



SDAI Limited
(Company Registration No. 201107179D)
(Incorporated in the Republic of Singapore on 25 March 2011)

FOR IMMEDIATE RELEASE

SDAI Secures Shareholders' Approval for Diversification into Biotechnology Business, Advancing Anti-Ageing and Healthcare Strategy

- Biotechnology industry is growing rapidly, presenting significant growth opportunities.
- Strategic progress includes partnership with LiveBeyond, launch of Bluecode Biotech B-III skincare series, and joint venture with Hubei Qiai to expand moxibustion products across ASEAN.
- The Group aims to establish a first-mover advantage in Asia's longevity sector and position itself as a leading brand in the region's anti-ageing industry

SINGAPORE, 7 May 2026 – SDAI Limited (the “**Company**” or “**SDAI**”, and together with its subsidiaries, the “**Group**”) has obtained approval from shareholders of the Company (“**Shareholders**”) on the proposed diversification of the Group's existing core business into the biotechnology business (“**Diversification**”) during the extraordinary general meeting of the Company held on 30 April 2026.

The biotechnology industry has emerged as a dynamic and rapidly expanding sector, driven by global population growth, advancements in anti-ageing and longevity science, evolving consumer preferences and increasing awareness of health and wellness. The global anti-ageing market size was estimated at US\$80.0 billion in 2025 and is projected to grow to US\$84.4 billion in 2026 and US\$137.1 billion by 2035, representing a compound annual growth rate of 5.5% over the forecast period¹. In Singapore, this growth is further supported by the Singaporean government's Research, Innovation and Enterprise 2030 (RIE2030) Plan, which will invest S\$37.0 billion in research and innovation over the next five years starting from April 2026. The first Research, Innovation and Enterprise Grand Challenge, “Maximising Healthy and Successful Longevity,” aims to address Singapore's rapid transition to a super-aged society by enhancing the understanding of the biology of ageing in the population and the ability to intervene early and effectively².

The Group is of the view that there are significant growth opportunities within the biotechnology industry and is well-positioned to capitalise on this rising trend. Thus, the Group decided to diversify its existing business to include biotechnology, encompassing

¹ <https://www.towardshealthcare.com/insights/anti-aging-market-sizing>

² Singapore unveils S\$37 billion RIE2030 Plan to advance research and innovation, and support Singapore's economic and national priorities, https://www.nrf.gov.sg/files/RIE2030_Press_Release_2030.pdf



SDAI Limited
(Company Registration No. 201107179D)
(Incorporated in the Republic of Singapore on 25 March 2011)

a broad range of activities related to the development, distribution and provision of anti-ageing and longevity-focused healthcare products and services.

The Group's ability to distinguish itself in a highly competitive market is underpinned by its pioneering role in establishing the biological age management sector. As an emerging "blue ocean" market with minimal direct competition, this space represents a key pillar of the Group's differentiation strategy and underscores its strong positioning for future growth.

The Group has established a proprietary technology platform that integrates modern scientific advancements with traditional herbal medicine, forming a key pillar of the Group's competitive strength. Recognising that differences in genetics and lifestyle may limit the effectiveness of Western-developed anti-ageing solutions for Asian populations, the Group leverages centuries-old herbal knowledge alongside cutting-edge life sciences to develop a differentiated product portfolio tailored specifically to Asian consumers. This distinctive approach not only enhances product relevance and efficacy but also establishes a strong and defensible competitive advantage, positioning the Group favourably within the rapidly evolving anti-ageing and healthcare landscape. Earlier this year, the Company was awarded "**Best Biotechnology Healthcare Solutions Development 2026 – Asia Pacific**"³ a recognition that underscores its competitive strengths and leadership in the sector.

The Diversification is expected to create new revenue streams, enabling the Group to better manage business risks and enhance its resilience to industry volatility. It also presents opportunities for geographical diversification, as the Group intends to explore biotechnology-related business opportunities across multiple markets. This approach provides the Group with greater flexibility to identify and capture emerging opportunities, while remaining adaptable to shifts in global economic and industry trends. In addition, the Diversification will allow the Group to pursue biotechnology-related transactions more efficiently, without the need to convene separate general meetings for each such transaction.

The Group has made steady progress in its biotechnology-driven transformation. As announced by the Group on 12 August 2025, the Group has, on 11 August 2025, entered into a strategic cooperation agreement with LiveBeyond Pte. Ltd. ("**LiveBeyond**") to jointly pursue research, development and application initiatives in the field of anti-ageing. LiveBeyond specialises in delivering a comprehensive range of services that empower individuals and organisations by providing access to cutting-edge longevity research and medical solutions. Leveraging on its strong research capabilities in the anti-ageing industry, LiveBeyond collaborates with global partners to translate emerging innovations such as biological age diagnostics, healthspan biomarkers, regenerative medicine and age-related therapeutics into credible and scalable solutions.

³ Awarded by APAC Insider – South East Asia Business Awards 2026



SDAI Limited
(Company Registration No. 201107179D)
(Incorporated in the Republic of Singapore on 25 March 2011)

Furthermore, as announced by the Group on 10 December 2025, the Group successfully launched its Bluecode Biotech B-III skincare series (“**B-III Series**”) in the People’s Republic of China and Singapore. Developed by its in-house research and development team, the B-III Series integrates advanced bioengineering and plant stem cell technology, with a focus on restoring cell-to-cell communication to activate the skin’s natural self-repair function. For more information on the products and activities, please visit www.b-iii.com.

As announced by the Group on 12 January 2026, the Group entered into a joint venture shareholders’ agreement on the same day with Hubei Qiai Group Co., Ltd., QCM Holdings Pte. Ltd. (“**QCMH**”) and QCM International Pte. Ltd. QCMH was incorporated to serve as an international platform to expand the market for moxibustion products in the ASEAN region. QCMH aims not only to promote mugwort products from Qichun, People’s Republic of China, but also to co-develop a holistic health ecosystem. The partnership between Hubei Qiai and SDAI is intended to bring traditional mugwort-based wellness solutions into modern, accessible formats through standardised products, integrated services and a sustainable business model, with the goal of reaching more consumers across ASEAN and beyond. In relation to QCMH, the Group has set up the first moxibustion experience centre at #01-04, 5 Jurong West Avenue 5, Singapore 649485 to educate customers and allow them to experience first-hand of the benefits of QCMH moxibustion products.

Madam Hao Dongting (郝东亭), Executive Chairperson of the Company, commented, “The Group is now well positioned to chart a new growth trajectory, following the successful transformation of our business into a biotechnology-focused platform specialising in anti-ageing and healthcare. We believe this diversification represents a strategic step forward, creating new business opportunities, generating additional revenue streams, and delivering long-term value to our Shareholders.

With several key initiatives completed, strategic partnerships established, and compliance frameworks in place, the Group is now focused on three core pillars: skin anti-ageing, anti-ageing supplements and solutions and mugwort-based moxibustion health management.

Our ultimate objective is to establish a first-mover advantage in Asia’s longevity sector, position the Group as a leading brand in the region’s anti-ageing industry, and transform healthy longevity into a measurable, accessible and scalable consumer offering. While we remain in the early stages of this transformation and recognise that it will take time for these efforts to translate into financial results, we are confident that we are on the right path towards achieving sustainable growth.”

- END -



SDAI Limited
(Company Registration No. 201107179D)
(Incorporated in the Republic of Singapore on 25 March 2011)

About SDAI Limited

Listed on the Catalist Board of the Singapore Exchange since July 2011, SDAI Limited ("**SDAI**", and together with its subsidiaries, the "**Group**") is undergoing a strategic transformation into a biotechnology company specialising in healthcare-related products and services.

As the first step in this biotechnology-driven transformation, the Group has launched the Bluecode Biotech B-III skincare series, an advanced line of plant stem cell skincare products.

The Group plans to integrate biotechnology across the medical, skincare, and health products industries and is committed to become a leading force in the biotechnology space. In addition, the Group is committed to advancing the globalisation of traditional Chinese moxibustion.

For more information, please visit www.sdai.com.sg

Issued for and on behalf of SDAI Limited by Woodnote Consulting

Yong Jing Wen

E: jingwen@woodnoteconsulting.com

T: (65) 9860 3047

*This press release has been reviewed by the Company's sponsor, ZICO Capital Pte. Ltd. (the "**Sponsor**").*

*This press release has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.*

The contact person for the Sponsor is Ms Yang Zhenni, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.